We are live on ! Find out more
CRBU icon

Caribou Biosciences

140 hedge funds and large institutions have $87.6M invested in Caribou Biosciences in 2024 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 41 increasing their positions, 43 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% less repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 43

7% less funds holding

Funds holding: 151140 (-11)

15.05% less ownership

Funds ownership: 73.91%58.86% (-15%)

25% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 36

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

67% less call options, than puts

Call options by funds: $54K | Put options by funds: $163K

74% less capital invested

Capital invested by funds: $343M → $87.6M (-$255M)

Holders
140
Holders Change
-11
Holders Change %
-7.28%
% of All Funds
2.02%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
27
Increased
41
Reduced
43
Closed
36
Calls
$54K
Puts
$163K
Net Calls
-$109K
Net Calls Change
-$182K
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
26
Wellington Management Group
Massachusetts
$858K +$260K +81,444 +18%
7IH
27
72 Investment Holdings
Connecticut
$777K
JP Morgan Chase
28
JP Morgan Chase
New York
$761K -$272K -85,026 -15%
DekaBank Deutsche Girozentrale
29
DekaBank Deutsche Girozentrale
Germany
$666K
Bank of New York Mellon
30
Bank of New York Mellon
New York
$506K +$122K +38,098 +14%
BC
31
Bruce & Co
Illinois
$492K +$320K +100,000 +50%
N
32
Nuveen
North Carolina
$439K
WP
33
Woodline Partners
California
$386K -$5.9K -1,846 -0.8%
Qube Research & Technologies (QRT)
34
Qube Research & Technologies (QRT)
United Kingdom
$361K +$703K +220,017 New
XT
35
XTX Topco
Cayman Islands
$341K +$665K +208,162 New
Mirae Asset Global ETFs Holdings
36
Mirae Asset Global ETFs Holdings
Hong Kong
$314K +$612K +191,562 New
RCA
37
Resonant Capital Advisors
Wisconsin
$302K
Aberdeen Group
38
Aberdeen Group
United Kingdom
$298K
AllianceBernstein
39
AllianceBernstein
Tennessee
$281K +$278K +86,930 +103%
Marshall Wace
40
Marshall Wace
United Kingdom
$271K -$650K -203,309 -55%
Walleye Capital
41
Walleye Capital
New York
$267K +$520K +162,800 New
CRC
42
Curi RMB Capital
Illinois
$253K +$194K +60,705 +65%
RA
43
Royce & Associates
New York
$234K -$371K -116,016 -45%
MAM
44
Milestone Asset Management
Pennsylvania
$233K +$455K +142,310 New
Prudential Financial
45
Prudential Financial
New Jersey
$222K +$172K +53,871 +66%
American Century Companies
46
American Century Companies
Missouri
$205K +$52.8K +16,530 +15%
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
$205K +$7.66K +2,398 +2%
Thrivent Financial for Lutherans
48
Thrivent Financial for Lutherans
Minnesota
$175K +$342K +106,985 New
UBS Group
49
UBS Group
Switzerland
$175K -$964K -301,739 -74%
AG
50
Artal Group
Luxembourg
$173K

CRBU Hedge Fund Activity: Q2 2024 in Review

140 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Caribou Biosciences (CRBU) for Q2 2024, worth a combined $87.6M — down 74% from $343M a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of CRBU and 27 opened new positions — a net loss of 9 holders — while 43 trimmed existing stakes and 41 added.

The largest buyer was Bank of America, adding an estimated $9.73M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $29.7M sold.

  • 140 institutional investors held Caribou Biosciences (CRBU) as of Q2 2024, down from 151 in Q1 2024.
  • Funds reported $87.6M of Caribou Biosciences stock for Q2 2024, down 74% quarter-over-quarter.
  • 27 funds opened new Caribou Biosciences positions in Q2 2024 and 36 closed out, a net change of -9 holders.
  • The largest Caribou Biosciences buyer in Q2 2024 was Bank of America, an estimated $9.73M added.
  • The largest Caribou Biosciences seller in Q2 2024 was Avidity Partners Management, an estimated $29.7M sold.

Based on aggregated 13F filings for Q2 2024.